SIRIO(SZ:300791)2023-04-27 16:00Financial Performance - The company's revenue for Q1 2023 was ¥702,158,705.58, representing a 66.69% increase compared to ¥421,248,609.14 in the same period last year[3]. - Net profit attributable to shareholders was ¥29,399,867.21, a 100.84% increase from ¥14,638,612.62 year-on-year[3]. - The net profit after deducting non-recurring gains and losses surged by 490.63% to ¥25,455,628.46 from ¥4,309,880.47 in the previous year[3]. - The company's diluted earnings per share increased by 102.55% to ¥0.1908 from ¥0.0942 in the same period last year[3]. - The net profit for Q1 2023 was CNY 18,758,317.18, an increase of 28.8% compared to CNY 14,638,612.62 in Q1 2022[35]. - The total revenue from operating activities was CNY 945,729,797.58, up from CNY 627,577,406.25 in the previous year, representing a growth of 50.8%[39]. - The operating profit for the quarter was CNY 24,965,230.25, compared to CNY 17,746,209.01 in the same period last year, marking a 40.5% increase[35]. Assets and Liabilities - The company's total assets increased by 11.55% to ¥4,669,180,197.02 from ¥4,185,817,139.24 at the end of the previous year[3]. - The total liabilities as of the end of Q1 2023 were 1,818,738,754.91 yuan, compared to 1,484,293,151.85 yuan at the beginning of the year, reflecting an increase in financial obligations[31]. - The company has made significant investments in fixed assets, with a total of 1,321,970,833.86 yuan reported at the end of Q1 2023, up from 1,235,145,651.08 yuan[30]. Cash Flow - Cash flow from operating activities decreased by 72.79% to ¥37,879,957.19 from ¥139,235,270.31 in the previous year, primarily due to transaction-related expenses from the acquisition of Best Formulations LLC[15]. - The company reported cash and cash equivalents of 487,896,996.45 yuan at the end of Q1 2023, down from 1,501,602,794.16 yuan at the beginning of the year[28]. - The company experienced a net cash outflow of CNY 901,559,301.32 during the quarter, compared to CNY -53,761,544.06 in the same period last year[40]. - The cash flow from operating activities showed a net increase of CNY 37,879,957.19, down from CNY 139,235,270.31 in Q1 2022[39]. Inventory and Expenses - The company reported a significant increase in inventory, which rose by 88.90% to ¥439,343,952.26, mainly due to the consolidation of Best Formulations[10]. - The company's sales expenses surged by 132.01% to ¥52,632,216.27, attributed to the recovery of marketing activities and expenses related to the acquisition of Best Formulations[12]. - The total operating costs for Q1 2023 were 683,269,157.07 yuan, up from 418,839,974.40 yuan in the previous year, indicating a significant increase in costs[34]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 7,436[17]. - Guangdong Guanghui Investment Co., Ltd. holds 43.08% of the shares, totaling 77,760,000 shares[17]. - Chen Qiong and Lin Peiqing, who are spouses, hold 7.47% and 7.18% of the shares respectively, totaling 13,478,400 and 12,960,000 shares[17]. - The total number of restricted shares at the end of the period is 27,823,417, with 85,536,000 shares released during the period[21]. Acquisition Details - The company completed the acquisition of 80% equity in Best Formulations Inc. on January 6, 2023, after fulfilling all conditions precedent[24]. - The acquisition of Best Formulations Inc. was adjusted to obtain approximately 71.41% of the equity through a combination of purchasing existing shares and increasing capital[23]. - The company has completed all necessary foreign investment filing procedures with the Guangdong Provincial Department of Commerce[23]. Other Financial Activities - The company raised a total of 102,489.29 million yuan by issuing 10,248,929 convertible bonds, with each bond having a face value of 100 yuan[25]. - The company has decided to redirect 10,531.66 million yuan originally allocated for the East China R&D Center to the soft capsule workshop technology upgrade project[25]. - The company reported a significant increase in cash outflow from investment activities, totaling CNY 728,378,578.08, compared to CNY 352,111,367.96 in the previous year[39]. - The total comprehensive income for the quarter was CNY -110,875,780.68, contrasting with CNY 14,138,814.21 in Q1 2022[36]. - Basic earnings per share increased to CNY 0.1629 from CNY 0.0812 year-over-year[36]. - The company reported a significant increase in credit impairment losses, amounting to CNY 1,699,011.21, compared to CNY 2,781,920.46 in the previous year[35].